Literature DB >> 5041685

Plasma 3-0-methyldopa in L-dopa therapy of Parkinson's disease.

M D Muenter, N S Sharpless, G M Tyce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 5041685

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN： 0025-6196            Impact factor:   7.616


× No keyword cloud information.
  10 in total

1.  Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease.

Authors:  Phylinda L S Chan; John G Nutt; Nicholas H G Holford
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

2.  Gout induced by L-dopa and decarboxylase inhibitors.

Authors:  D B Calne; J Fermaglich
Journal:  Postgrad Med J       Date:  1976-04       Impact factor: 2.401

Review 3.  Clinical pharmacokinetics of anti-parkinsonian drugs.

Authors:  J M Cedarbaum
Journal:  Clin Pharmacokinet       Date:  1987-09       Impact factor: 6.447

4.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

5.  Effect of duration of levodopa/decarboxylase inhibitor therapy on the pharmacokinetic handling of levodopa in elderly patients with idiopathic Parkinson's disease.

Authors:  S G Bowes; C J O'Neill; P W Nicholson; A L Leeman; A A Deshmukh; R J Dobbs; S M Dobbs
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

6.  Synergistic interactions between COMT-/MAO-inhibitors and L-Dopa in MPTP-treated mice.

Authors:  A Fredriksson; T Archer
Journal:  J Neural Transm Gen Sect       Date:  1995

7.  Parkinsonian abnormality of foot strike: a phenomenon of ageing and/or one responsive to levodopa therapy?

Authors:  J R Hughes; S G Bowes; A L Leeman; C J O'Neill; A A Deshmukh; P W Nicholson; S M Dobbs; R J Dobbs
Journal:  Br J Clin Pharmacol       Date:  1990-02       Impact factor: 4.335

8.  Low catechol-O-methyltransferase activity in a Saami population.

Authors:  B Klemetsdal; B Straume; T Giverhaug; J Aarbakke
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

9.  Catechol-O-methyltransferase inhibition by U-0521 increases striatal utilization of levodopa.

Authors:  A Reches; D Jiang; S Fahn
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

10.  Substantia nigra degeneration and tyrosine hydroxylase depletion caused by excess S-adenosylmethionine in the rat brain. Support for an excess methylation hypothesis for parkinsonism.

Authors:  C G Charlton; J Mack
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.